Abstracts tagged "Biologics"

Abstract Number: 925 • 2017 ACR/ARHP Annual Meeting
Open-Source Conensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care
Devin Incerti¹, Jeffrey R. Curtis², Maria Lorenzi¹ and Jeroen Jansen¹, ¹Innovation and Value Initiative, Oakland, CA, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The treatment and prognosis of moderate to severe rheumatoid arthritis has improved considerably due to the advent of biological therapies. But at the same…
Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting
Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis
Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan
Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting
Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
Hannah Schenker¹, Andreas Hess², Laura Konerth², Marina Sergeeva², Jutta Prade², Arnd Kleyer¹, Michaela Reiser¹, Axel J. Hueber¹, Matthias Englbrecht¹, Eugen Feist³, Reinhard Voll⁴, Bettina Bannert⁴, C Baerwald⁵, Julie Rösch⁶, Arnd Dörfler⁷, José António P. da Silva⁸, Nemanja Damjanov⁹, Georg Schett¹ and Juergen Rech¹, ¹Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology and Clinical Immunology, Charité, Berlin, Berlin, Germany, ⁴Clinic for Rheumatology and Clinical Immunology, Medical University of Freiburg, Germany, Freiburg, Germany, ⁵Department of Rheumatology, University of Leipzig, Germany, Leipzig, Germany, ⁶Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ⁷Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, e, Germany, ⁸Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…
Abstract Number: 2591 • 2017 ACR/ARHP Annual Meeting
Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab
Victoria P Werth¹, Gabor Illei², Gabriel Abreu³, Liangwei Wang² and Warren Greth², ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²MedImmune, Gaithersburg, MD, ³AstraZeneca, Gothenburg, Sweden
Background/Purpose: Studies have demonstrated an association between smoking and more severe cutaneous lupus erythematosus, resulting in decreased health-related quality of life and treatment response.1 We…
Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
Abstract Number: 953 • 2017 ACR/ARHP Annual Meeting
Persistence of Pathogenic CD4 Memory T Cells Revealed through Cytometry Time of Flight in Juvenile Idiopathic Arthritic Patients with Disease Resurgence upon Withdrawal of Anti-TNFA Biologics
Jing Yao Leong¹, Joo Guan Yeo², Phyllis Chen³, Liyun Lai⁴, Fauziah Ally⁵, Loshinidevi D/O Thana Bathi³, Justin Hung Tiong Tan², Thaschawee Arkachaisri², Femke van Wijk⁶, Salvatore Albani⁴, Daniel J Lovell⁷ and Gerdien Mijnheer⁸, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁴SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁵STIIC, SingHealth Translational Immunology and Inflammation Centre, Singapore, Singapore, ⁶University Medical Center Utrecht, Utrecht, Netherlands, ⁷Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁸1Laboratory of Translational Immunology, Department of Paediatric Immunology, , The Netherlands, University Medical Centre Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands
Background/Purpose: Treatment of polyarticular JIA with anti-TNFA biologics has experienced significant success, with up to 80% of patients demonstrating clinically meaningful efficacy. Yet concerns regarding…
Abstract Number: 1465 • 2017 ACR/ARHP Annual Meeting
Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
J Foo¹, JM Rodriguez Heredia², C Polanco Sánchez³, M Mtibaa⁴, KH Herrmann⁵, E Alemao⁶, R Postema⁷ and C Baerwald⁸, ¹Mapi Group, Houten, Netherlands, ²Hospital Universitario de Getafe, Madrid, Spain, ³Bristol-Myers Squibb, Madrid, Spain, ⁴Bristol-Myers Squibb, Montréal, QC, Canada, ⁵Bristol-Myers Squibb, Munich, Germany, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁸University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany
Background/Purpose: RA is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden.…
Abstract Number: 2266 • 2017 ACR/ARHP Annual Meeting
Patient Knowledge, Attitudes, and Beliefs Regarding Biologic Therapies in Ankylosing Spondylitis (AS): Insights from a Large-Scale Analysis of Social Media Platforms
Deeba Minhas¹, Benjamin Noah², Eldin Dzubur², Christopher Almario³, Mariko Ishimori¹, Corey Arnold⁴, Amber Howard², Carine Khalil², Alma Jusufagic², Michelle Chen², Jina Park⁵, Michael Weisman¹ and Brennan Spiegel³, ¹Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ²Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA, ³Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Cedars-Sinai Medical Center Division of Digestive and Liver Diseases, Los Angeles, CA, ⁴Medical Imaging Informatics, Department of Radiology, University of California Los Angeles, Los Angeles, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: While there are multiple biologic options for ankylosing spondylitis (AS), few attempts have been made to examine patients’ knowledge and understanding of these therapies…
Abstract Number: 2605 • 2017 ACR/ARHP Annual Meeting
Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
Shereen Oon^1,2, Molla Huq², Timothy Godfrey³ and Mandana Nikpour^1,2, ¹Rheumatology, St Vincent's Hospital, Melbourne, Australia, ²Medicine, The University of Melbourne, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia
Background/Purpose: There is a pressing need for novel biologic therapies in systemic lupus erythematosus (SLE). We sought to systematically review the outcomes of recent phase…
Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers², Sara Gale³, Micki Klearman³, Khaled Sarsour³ and Sebastian Schneeweiss², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Genentech, South San Francisco, CA
Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 1475 • 2017 ACR/ARHP Annual Meeting
Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort
Mohammad Movahedi, Angela Cesta, Xiuying Li and Claire Bombardier, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Collection of Anti-Rheumatic Medication (ARM) information from both patients and rheumatologists is considered a strength for Rheumatoid Arthritis (RA) registries and cohorts. However, it…
Abstract Number: 2291 • 2017 ACR/ARHP Annual Meeting
Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis: First Results of Clinical Outcome after 24 Months
Petra Hissink Muller^1,2, Danielle Brinkman^1,3, Dieneke Schonenberg-Meinema⁴, Yvonne Koopman-Keemink⁵, Wytse van den Bosch⁶, Isabel Brederije¹, Peter Bekkering⁷, Taco Kuijpers⁴, Marion van Rossum⁸, Lisette van Suijlekom-Smit², J Merlijn van den Berg⁴, CF Allaart⁹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Pediatrics, Alrijne Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Hematology, Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Pediatrics, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Department of Pediatrics, Haaglanden Medical Center, The Hague, Netherlands, ⁷Department of Physiotherapy, Prinses Maxima Pediatric Oncology Center, Utrecht, Netherlands, ⁸Department of Pediatric Rheumatology, Amsterdam Rheumatology and Immunology Center location Reade Amsterdam, Amsterdam, Netherlands, ⁹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The BeSt treatment strategy for children with juvenile idiopathic arthritis (JIA) has not been determined. The aim of the BeSt for Kids study was…
Abstract Number: 2755 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic DMARDs have varying mechanisms of action and may be associated with different infection risks. The perioperative time period is a particularly high-risk time…
Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Joost Swart¹, Nico Wulffraat², Sytze de Roock³ and Pieter van Dijkhuizen⁴, ¹Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].